A number of clinical programs are in development featuring our tetravalent bispecific ICE® (innate cell engager) molecules based on the ROCK® (Redirected Optimized Cell Killing) platform, and have already shown a favorable safety profile and promising signs of therapeutic efficacy.

Acimtamig (AFM13) is a first-in-class ICE® molecule that has the potential to deliver clinically meaningful benefits to patients with CD30+ lymphomas.1

AFM24 is an EGFR-binding ICE® molecule that kills EGFR-expressing tumors, and through ADCC and ADCP, holds promise to treat patients with a more acceptable safety profile compared with current advanced treatments, while remaining immune to the challenge of resistance.2

AFM28 is an ICE® that binds to CD123 on leukemic cells and is being developed for patients with relapsed and refractory acute myeloid leukemia (AML).

Innate Cell Engagers

Pre-Clinical
Phase 1
Phase 2
Additional Information
Disease Target CD30

AFM13-202 MONOTHERAPY

Peripheral T cell lymphoma
Phase 2b
Completed

AFM13-203 + ADOPTIVE NK CELLS

CD30-positive lymphoma
Phase 2
Enrolling, Collaboration with

AFM13-104 + ADOPTIVE NK CELLS

CD30-positive lymphoma
Phase 1/2a
Ongoing

AFM13-103 + ANTI-PD-1

Hodgkin lymphoma (post BV)
Phase 1b
Completed
Disease Target EGFR

AFM24-101 MONOTHERAPY

Multiple EGFR+ solid tumors
Phase 1/2a
Active, Not Recruiting

AFM24-102 + ANTI-PD-L1

Multiple EGFR+ solid tumors
Phase 1/2a
Ongoing

AFM24-103 + ADOPTIVE NK CELLS

Multiple EGFR+ solid tumors
Phase 1/2a
Active, Not Recruiting
Disease Target CD123

AFM28-101 MONOTHERAPY

Acute Myeloid Leukemia (AML)
Phase 1
Ongoing

AFM28 + ADOPTIVE NK CELLS

Acute Myeloid Leukemia (AML)
Pre-Clinical
Pre-IND
Disease Target FRα

AFVT-2101 (AFM32) - AFFIVANT

Solid tumors
Pre-Clinical
Pre-IND, Partnered with
Disease Target Undisclosed

Novel ICE® - GENENTECH

Multiple indications (not disclosed)
Pre-Clinical
Pre-IND, Partnered with
Disease Target Undisclosed

Novel ICE®

Multiple indications (not disclosed)
Pre-Clinical
Pre-IND
BV = brentuximab vedotin
CD = cluster of differentation
EGFR = epidermal growth factor receptor
FRα = Folate receptor alpha
ICE® = innate cell engager
IND = investigational new drug
NK = natural killer
PD-1 = programmed death protein1
PD-L1 = programmed death ligand 1
Affimed programs
Partnered programs
List is not exhaustive


See all Publications and Posters

Expanded Access Policy

Affimed does not currently have an expanded access program for our investigational products. Expanded access, also known as compassionate use, is a potential pathway for a patient with an immediately life-threatening condition or serious disease to gain access to an investigational drug for treatment outside of clinical trials when no comparable or satisfactory alternative therapy options are available.

We are focused on enrolling and conducting the clinical trials necessary to bring innovative, safe, and effective products to patients as quickly as possible. Participation in one of our clinical trials is the only way to access Affimed’s investigational products at this time. We encourage patients and healthcare providers interested in our investigational products to learn more about our ongoing studies by visiting Affimed Clinical Studies on our website. For more information, please contact us at info@affimed.com

ADCC=antibody-dependent cellular cytotoxicity; ADCP=antibody-dependent cellular phagocytosis; EGFR=epidermal growth factor receptor; IND=investigational new drug; NK=natural killer.

References: 1. Rothe A, Sasse S, Topp MS, et al. A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2015;125(26):4024-4031. 2. Reusch U, Damrat M, Wingert S, et al. AFM24, a bispecific EGFR/CD16A innate cell engager with the potential to overcome resistance to current targeted treatments for EGFR-positive malignancies. Poster presented at: American Association for Cancer Research (AACR) Annual Meeting; June 22-24, 2020; Virtual. Poster 5659.